Neuronetics, Inc.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
STIM$2.18+1.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Equity
(In thousands)
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · Additional · · · · · · | |||||||||||||||||
| · · Common Stock · · Paid-in · · Accumulated · · Noncontrolling · · Total | |||||||||||||||||
| · · Shares · · Amount · · Capital · · Deficit · · Interest · · Equity | |||||||||||||||||
| Balance at December 31, 2022 | 27,268 | | $273 | | $402,679 | | $(345,892) | | — | | $57,060 | ||||||
| Share-based awards and options exercises | 1,824 | | 18 | | (18) | | — | | — | | — | ||||||
| Share-based compensation expense | — | | — | | 7,319 | | — | | — | | 7,319 | ||||||
| Net loss | — | | — | | — | | (30,189) | | — | | (30,189) | ||||||
| Balance at December 31, 2023 | 29,092 | | 291 | | 409,980 | | (376,081) | | — | | 34,190 | ||||||
| Share-based awards and options exercises | 1,282 | | 13 | | (13) | | — | | — | | — | ||||||
| Issuance of warrants, net of issuance costs of $49 | | — | | | — | | | 2,521 | | | — | | | — | | | 2,521 |
| Issuance of stock as purchase consideration in connection with acquisition | | 25,305 | | | 253 | | | 28,848 | | | — | | | 4,112 | | | 33,213 |
| Share-based compensation expense | — | | — | | 5,602 | | — | | — | | 5,602 | ||||||
| Net loss | — | | — | | — | | (43,708) | | (19) | | (43,727) | ||||||
| Balance at December 31, 2024 | 55,679 | | 557 | | 446,938 | | (419,789) | | 4,093 | | 31,799 | ||||||
| Share-based awards and options exercises | 1,853 | | 18 | | (6) | | — | | — | | 12 | ||||||
| Issuance of common stock, net of issuance costs of $1,731 | | 9,200 | | | 92 | | | 18,877 | | | — | | | — | | | 18,969 |
| Issuance of common stock under ATM offering, net of issuance costs of $472 | | 2,262 | | | 23 | | | 7,818 | | | — | | | — | | | 7,841 |
| Share-based compensation expense | — | | — | | 6,848 | | — | | — | | 6,848 | ||||||
| Net loss | — | | — | | — | | (38,998) | | (137) | | (39,135) | ||||||
| Distribution to non-controlling interest | | — | | | — | | | — | | | — | | | (94) | | | (94) |
| Balance at December 31, 2025 | 68,994 | | $690 | | $480,475 | | $(458,787) | | $3,862 | | $26,240 | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.